Compare Tempus AI (TEM) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Tempus AI vs Zoetis Inc — how do they compare? Tempus AI trades at $49.1 (market cap $8.69B), while Zoetis Inc trades at $76.07 (market cap $31.95B). The key difference: Zoetis Inc is far larger — about 3.7× Tempus AI's market cap, and Zoetis Inc pays a 2.78% dividend while Tempus AI pays none. Which is the better fit depends on your goals.
| TEM | ZTS | |
|---|---|---|
Market Cap | $8.69B | $31.95B |
Sector | Broad Market / Factor | Health |
52-Week High | $103.25 | $156.76 |
52-Week Low | $42.37 | $71.91 |
Enterprise Value | $9.37B | $39.24B |
Dividend Yield | — | 2.78% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Tempus AI (TEM) trades at $48.41, down 7.74% in the last 24 hours, reflecting a bearish technical signal. The company reported revenue of $1.27 billion in 2025 but a net loss of $245.03 million, with negative profitability metrics. Recent news highlights growth in AI-driven diagnostics and data services, including FDA approvals and research collaborations. The stock is trading well below the analyst consensus price target of $68.50, with a majority of analysts maintaining a Buy rating.
The outlook for TEM is a mix of high growth potential in healthcare AI and significant financial risk due to persistent losses. Investment opportunity lies in its proprietary data platform and expanding market reach, but risks include execution challenges and cash burn. Wall Street sentiment remains positive on long-term prospects, but investors should weigh the volatility against the company's unproven path to profitability.
No Aura AI signal available yet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Tempus AI
Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
